💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Incyte Corporation (INCY)
« Back to company indexINCY Chatter Timeline
Stock Ticker for INCY
Most Active Tweeters for INCY
| User | Tweets |
|---|---|
| @Tickeron | 8 |
| @MarcJacksonLA | 7 |
| @TradeWithAlerts | 6 |
| @sleekoptions | 6 |
| @FlashAlert_me | 6 |
Recent Tweets for INCY
 |
@Tickeron $INCY in Uptrend: price expected to rise as it breaks its lower Bollinger Band on May 4, 2021. View odds for this a… https://t.co/0PtagkjkzL May 8th 2021, 9:05am |
 |
@TradeWithAlerts Nice Print for $INCY - Amount: $11,072,928.72 - to learn more, SIGNUP https://t.co/JWvlYbvmfL or get a training https://t.co/0L4k6hF6bT! May 7th 2021, 8:05pm |
 |
@stevedoc22 @DeepSouthDoctor The concern is that they do not have freedom to operate due to $INCY IP. Also, they are chronic screw-ups. May 6th 2021, 8:05pm |
 |
@MarcJacksonLA $INCY Evercore Maintains Buy Rating On Incyte, $115 PT https://t.co/kkw8DQnIB8 May 6th 2021, 2:05pm |
 |
@Jarvis_Alerts $INCY [Incyte]: Morgan Stanley Maintains Equal-Weight Lowers Price Target $86 --> 85 https://t.co/9DjGO6tIcC May 6th 2021, 12:05pm |
|
@Tickeron $INCY in Uptrend: price expected to rise as it breaks its lower Bollinger Band on May 4, 2021. View odds for this a… https://t.co/iYVPCE694D May 6th 2021, 9:05am |
 |
@adar170 $INCY was -28% https://t.co/kLIe56fsls May 6th 2021, 1:05am |
 |
@InsiderForms $INCY Insider Dhanak Dashyant has Sold 396 Shares. Title :EVP; Chief Scientific Officer Total Cost: $33,818.4 Buy/S… https://t.co/kjmx4qudEZ May 5th 2021, 8:05pm |
 |
@fintel_io Insider Dashyant Dhanak reports selling 396 shares of $INCY for a total cost of $33,818.40 https://t.co/14MCG8MJLZ May 5th 2021, 8:05pm |
|
@TradeWithAlerts Nice Print for $INCY - Amount: $9,912,948.00 - to learn more, SIGNUP https://t.co/JWvlYbdLod or get a training https://t.co/0L4k6hWHAt! May 5th 2021, 7:05pm |
|
@MarcJacksonLA $INCY Oppenheimer Maintains Buy Rating On Incyte, $110 PT https://t.co/pCID8Wfkoo May 5th 2021, 5:05pm |
 |
@CSIMarket $INCY #StockMarket #yte released fiscal first quarter of 2021 Revenues on https://t.co/savSNTKlN1: INCY announced E… https://t.co/o6UgZhLT9Z May 5th 2021, 12:05pm |
 |
@SwingTradeBot $INCY technical alerts: Stochastic Sell Signal, Wide Range Bar, Fell Below 50 DMA, MACD Bearish S... https://t.co/w5vDMJe2Lv May 5th 2021, 12:05pm |
 |
@CHItraders $INCY Morgan Stanley Maintains Equal-Weight on Incyte, Lowers Price Target to $85 May 5th 2021, 12:05pm |
 |
@realmaciej RT @semodough: $INCY catalysts from there side deck https://t.co/FmG9dvUlZ0 May 5th 2021, 7:05am |
 |
@sleekoptions Peak profit for the last 6 expired option alerts for $INCY 15.56% | 1.48% | 18.57% | -98.48% | 52.08% | 159.58% |… https://t.co/oqAod4RLoo May 5th 2021, 12:05am |
|
@sleekoptions $INCY - Last six months, 6 option alerts peaked above 100% after they were triggered by the algo… https://t.co/TkKDOqeb9K May 5th 2021, 12:05am |
|
@sleekoptions $INCY - View historical options performance for INCY https://t.co/fBAay8o89T https://t.co/mMkuSiMQo6 May 5th 2021, 12:05am |
|
@MarcJacksonLA $INCY Pharma company to pay $12.6M to settle kickback allegations https://t.co/oTzpeDYOMj May 4th 2021, 11:05pm |
 |
@CryptoNewswire Pharma company to pay $12.6M to settle kickback allegations - https://t.co/0WyZh2bfIP $INCY #trading #crypto #news May 4th 2021, 10:05pm |
|
@sleekoptions $INCY stock trading volume up by +153.22% | 1,846,688 vs 729,281 https://t.co/ksN8HlN6pO May 4th 2021, 8:05pm |
 |
@EdgarInsider New Form 10-Q [Quarterly Report] entry filed by $INCY INCYTE CORP https://t.co/ijDtXo0Agu May 4th 2021, 8:05pm |
|
@fintel_io $INCY / Incyte files form 10-Q https://t.co/Oc4NyYycjO May 4th 2021, 8:05pm |
|
@SwingTradeBot 50 DMA Support today: $INCY $KNSL ... https://t.co/aW7zteKP9U May 4th 2021, 7:05pm |
|
@TradeWithAlerts Nice Print for $INCY - Amount: $11,730,105.50 - to learn more, SIGNUP https://t.co/JWvlYbdLod or get a training https://t.co/0L4k6hWHAt! May 4th 2021, 7:05pm |
 |
@Swing_Samurai $INCY: Sell-to-open a partial/starter SHORT position. Bullish Aggression Score: [hidden] / Bearish Aggression Score… https://t.co/dTYABUJJ8L May 4th 2021, 7:05pm |
 |
@AlertTrade DOWNwithEARNINGS: $INCY Incyte Corporation Common Stock https://t.co/PDXLLWRMEb ? TradeIdeas via ? https://t.co/VS8RO1bzXJ May 4th 2021, 6:05pm |
 |
@SiteFocusHQ $INCY Earnings Intelligence Analysis of recent earnings identified Incyte Corp. (NASDAQ: INCY ) business focus on… https://t.co/AHGphCAGCr May 4th 2021, 6:05pm |
 |
@SeekingAlpha $INCY - Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q1 2021 Results - Earnings Call Transcript.… https://t.co/pKjTUWuLGR May 4th 2021, 6:05pm |
 |
@newsfilterio Incyte's Q1 Jakafi Sales Hit By Pandemic; Reaffirms 2021 Guidance $INCY https://t.co/PqlGxuKzA0 May 4th 2021, 6:05pm |
 |
@equity_newswire $INCY Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs https://t.co/wYsmIyWwlG May 4th 2021, 5:05pm |
 |
@EarningsAlley Incyte Corporation $INCY held an earnings call on 5/4/2021. Here are the highlights: May 4th 2021, 4:05pm |
 |
@StckPro $INCY NEW ARTICLE : Incyte's Q1 Jakafi Sales Hit By Pandemic; Reaffirms 2021 Guidance https://t.co/PibwrHNU7G Get a… https://t.co/oSe74Q5Zoh May 4th 2021, 4:05pm |
|
@SeekingAlpha $INCY - Incyte Corporation 2021 Q1 - Results - Earnings Call Presentation. https://t.co/3XKMPuWnId #stockmarket #finance #markets May 4th 2021, 3:05pm |
|
@MarcJacksonLA $INCY Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs | Business… https://t.co/yHOpimRJTY May 4th 2021, 2:05pm |
 |
@optioncharts $INCY Max Pain=80.00. Maturity=05/21/2021. #maxpain #options https://t.co/hfpe0Iy6CV https://t.co/s8ZxCAZ3Pa May 4th 2021, 2:05pm |
 |
@Briefingcom $INCY: Incyte beats by $0.04, misses on revs; reaffirms FY21 guidance https://t.co/PraYbpAA4R May 4th 2021, 1:05pm |
 |
@glitchbotio RT @MarketCurrents: $INCY - Incyte posts mixed Q1 results, reaffirms guidance https://t.co/1n6Z8AoCTV May 4th 2021, 12:05pm |
 |
@MarketCurrents $INCY - Incyte posts mixed Q1 results, reaffirms guidance https://t.co/1n6Z8AoCTV May 4th 2021, 12:05pm |
 |
@mikelbarun $INCY playing star wars music during their 1Q21 earnings call is the pick me up I didnt know I needed this morning May 4th 2021, 11:05am |
 |
@StockPods $INCY Earnings Call Today: 8:00 AM EST Webcast: https://t.co/CNiDdf5wPE Signup for the StockPods BETA now: https://t.co/Vma4E2hQ99 May 4th 2021, 11:05am |
 |
@earningsinfo $INCY Incyte Corp Q1 2021 Earnings Call https://t.co/GQPVciSy8i May 4th 2021, 11:05am |
 |
@mediasentiment $INCY new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 376 May 4th 2021, 11:05am |
|
@mediasentiment $INCY new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 375 May 4th 2021, 11:05am |
 |
@BertrandBio $INCY no specific figure for $MOR tafasitamab/Monjuvi, just "good uptake by both academic and community physicians"… https://t.co/d8ieyJHen1 May 4th 2021, 11:05am |
 |
@StockTexts $INCY Incyte Corporation SEC Filing: Form 8-K https://t.co/sNcnosdBM0 May 4th 2021, 11:05am |
 |
@Estimize Great work by Suntrust_115 who takes the win for $INCY beating 8 other analysts and the Wall Street Consensus - https://t.co/yXcR4cazfj May 4th 2021, 11:05am |
|
@Estimize $INCY misses the Estimize EPS Consensus by 3c and the Estimize Revenue Consensus by $66.18M. Reports FQ1 earnings o… https://t.co/HBtaCxv5v7 May 4th 2021, 11:05am |
|
@Estimize $INCY reports FQ1 earnings of 67c EPS and $604.72M Revs - https://t.co/yDuYYVADP1 May 4th 2021, 11:05am |
|
@mediasentiment $INCY new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 330 May 4th 2021, 11:05am |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.
Get the DrugPatentWatch Daily Briefing
Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
Want insights into the biggest revenue-changing events?
Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
➤ Free Trial
